Skip to Content
MilliporeSigma
  • Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla.

Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla.

Vaccine (2006-10-24)
Muneki Hotomi, Masaki Suzumoto, Koju Itahashi, Jun Nagura, Takayoshi Fukushima, Jun Shimada, Dewan S Billal, Kazuma Yamauchi, Keiji Fujihara, Noboru Yamanaka
ABSTRACT

An animal model of otitis media using chinchillas was developed to evaluate the efficacy of tebipenem pivoxil (TBM-PI) against experimental otitis media. Chinchillas inoculated via the transbullar approach with Streptococcus pneumoniae serogroup 6 were included in the efficacy study with TBM-PI, amoxicillin (AMX) or untreated as controls. TBM-PI resulted in survival rate of 83%, compared with 25% survival for AMX and 0% survival for controls (p<0.01). Quantitative cultures in the middle ear effusions at day 5 of the TBM-PI group yielded 3.5+/-2.4log(10)CFUs/ml. TBM-PI is a promising antibiotic for the treatment of acute otitis media.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tebipenem pivoxil, ≥98% (HPLC)